Biotech Values

[rkrw]

I agree, a teva is big enough where they can file now with an eye on something to launch 10 years from now. Smaller generic companies may not have that luxury.

As far as the deal, if they did better than $25M upfront I'd be surprised. The compound looks good but it's early!